Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotrovimab Prophylaxis Against COVID-19 in Immunocompromised Individuals
NCT05210101Phase 2Completed
- Start
- Feb 2022
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotrovimab in coronavirus disease 2019 (COVID-19). Primary endpoints: Proportion of Patients With Treatment-emergent Adverse Events, Serious Adverse Events, and Adverse Events of Specific Interest at 36 weeks and Half-life of Sotrovimab at Day 168. Started Feb 2022; status: completed.
02
Drugs
sotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05210101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05210101.